Company Registration
NGO Registration
Virtual business address
Startup Registration
Shop Act Registration
Annual Compliance
Income tax Filing
Trade License Registration
BIS Registration main
CDSCO Registration
Star Rating Certification
WPC Registration
Brand Registration
Legal Metrology Certification
PESO certification
Factory License Registration
Fire NOC
AERB Certification
PSARA License
Fssai License
RCMC Certification
Import Export Registration
China Food Export
RNI Certification
NSIC Registration
ISO Certification Main
US FDA
ICEGATE Registration Main
CPCB Approval
EIA Environment
CPCB/SPCB
E-Waste Management
Plastic Waste Management
Battery Waste Management
Sat, Sep 05 2026
Raju Karn
The pharmaceutical industry in India operates under a detailed regulatory framework designed to ensure that medicines are safe, effective, and meet required quality standards. The Central Drugs Standard Control Organization (CDSCO) plays a key role in regulating drugs and coordinating important regulatory activities across India.
If your business is involved in drug manufacturing, importing, new drug development, clinical trials, or pharmaceutical distribution, understanding the applicable licensing requirements is essential for legal compliance and smooth market entry.
This guide explains the CDSCO licensing process in India, major types of approvals, required documents, SUGAM portal process, applicable authorities, fees, timelines, and important regulatory updates for 2026.
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory authority for drugs, medical devices, and cosmetics under the Directorate General of Health Services, Ministry of Health & Family Welfare.
CDSCO performs important regulatory functions under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and other applicable regulations.
Its responsibilities include:
For drug imports, CDSCO states that applications for Registration Certificates and Import Licences are processed under the applicable provisions of the Drugs and Cosmetics Rules through the SUGAM online system.
Obtaining the correct regulatory approval is important before carrying out regulated pharmaceutical activities in India.
Depending on the product and business activity, the applicable approval or licence may be required for:
Proper licensing helps businesses:
It is important to identify the correct licence before applying, because CDSCO and State Licensing Authorities have different regulatory responsibilities.
CDSCO-related approval or licensing requirements may apply to:
The exact requirement depends on the type of drug, intended activity, applicant, manufacturing site, and applicable regulatory category.
There is no single licence called a "CDSCO licence" that applies to every pharmaceutical business. Different activities require different permissions.
For drug imports, CDSCO's Import & Registration division identifies Form 41 as the Registration Certificate and Form 10/10A as applicable Import Licences for specified bulk drugs and finished formulations.
One of the most important things to understand is the difference between CDSCO and the State Licensing Authority (SLA).
CDSCO handles important central regulatory functions such as:
State authorities are involved in licensing and regulating activities such as applicable:
Therefore, a pharmaceutical company should not assume that every drug-related licence is issued directly by CDSCO.
The applicable authority depends on the activity and product.
For example:
Drug import → CDSCO
Domestic drug manufacturing → applicable State Licensing Authority and, where required, CDSCO involvement
New drug/clinical trial → CDSCO-related approval framework
The correct regulatory route should be determined before submitting an application.
The CDSCO licensing process depends on the type of drug, product, and approval required. The general process includes:
Choose the applicable approval, such as Import Licence, Registration Certificate, Manufacturing Licence, New Drug Approval, Clinical Trial Permission, or Test Licence.
Review the drug category, composition, intended use, manufacturing site, country of origin, labelling, and applicable regulatory requirements.
Prepare the required application forms, product details, manufacturing documents, GMP certificates, stability data, labelling, Free Sale Certificate, and authorisation documents, as applicable.
Submit the applicable CDSCO application online through the SUGAM portal with the required documents and fees.
CDSCO reviews the application and may raise queries, request additional documents, or seek clarification.
For applicable applications, CDSCO or the concerned authority may inspect the manufacturing facility, quality systems, documentation, and GMP compliance.
Once all requirements are satisfied, the relevant CDSCO approval, certificate, or licence is issued. The timeline varies by licence type, product category, documentation, and regulatory review.
The documents required for CDSCO licensing depend on the type of application, product, and business activity. Common requirements include:
Note: The exact document list varies depending on the CDSCO licence, drug category, product type, applicant, and regulatory pathway. Applicants should verify the latest CDSCO requirements before submission.
The approval timeline varies depending on the type of application.
Factors that can affect the timeline include:
For this reason, businesses should avoid treating a general timeline such as "1 to 6 months" as a guaranteed approval period.
A complete and properly prepared application can help reduce avoidable delays.
The SUGAM portal is an important online platform used for submitting and tracking various CDSCO regulatory applications.
Depending on the application type, applicants can use the system for:
CDSCO continues to use SUGAM for regulatory submissions. For example, its 2026 public notices include provisions for submitting Periodic Safety Update Reports for new drugs through SUGAM and other application-related processes.
CDSCO continues to update India's pharmaceutical regulatory framework during 2026.
Some notable developments listed on CDSCO's official notifications include:
For example, CDSCO published a July 2026 notification concerning debarment of applicants for submitting misleading, fake, or fabricated documents. It also issued a June 2026 notification concerning additional categories under Schedule H2.
CDSCO also published a June 2026 circular regarding implementation of the pharmacovigilance system under Schedule M and a March 2026 guidance document on dossier-based licensing of drugs for uniform product licensing.
Because pharmaceutical regulations can change frequently, applicants should verify the latest CDSCO notification, circular, rule, and applicable guidance before submitting an application.
Pharmaceutical companies often face challenges during the licensing process.
Choosing the wrong application category can result in delays and additional regulatory queries.
Missing documents, inconsistent information, or outdated certificates can affect application processing.
Product composition, stability data, manufacturing information, and quality documents must be prepared carefully.
CDSCO may raise technical or documentary queries that require accurate and timely responses.
Drug regulations and regulatory procedures can change through new notifications and circulars.
Foreign manufacturers may need an Indian authorised agent and specific registration documentation before importing applicable products.
Planning to manufacture, import, or launch pharmaceutical products in India?
Contact PSR Compliance for professional assistance with CDSCO licensing and regulatory approvals.
Call: +91 8796104190Email: support@psrcompliance.com
CDSCO licensing is an important part of pharmaceutical regulatory compliance in India. However, the applicable approval depends on the nature of the product, business activity, manufacturing or import arrangement, and regulatory category.
Businesses may need different approvals for drug imports, manufacturing, clinical trials, new drugs, testing, registration, and distribution.
A successful application requires the correct regulatory pathway, accurate documentation, appropriate technical information, and timely responses to regulatory queries.
Since CDSCO regulations and procedures continue to evolve, applicants should always verify the latest requirements before filing.
For businesses that need professional assistance, PSR Compliance can help with licence selection, documentation, SUGAM submission, regulatory coordination, and post-approval support.
CDSCO licensing refers to the applicable licences, registrations, permissions, and regulatory approvals required for specified pharmaceutical activities regulated by CDSCO and the applicable drug laws in India.
Depending on the activity, pharmaceutical manufacturers, drug importers, foreign manufacturers, clinical trial sponsors, and companies involved in specified new drugs or regulated pharmaceutical products may require CDSCO approval or licensing.
SUGAM is an online CDSCO platform used for submitting and managing various regulatory applications and related communications.
Documents vary according to the licence. Common requirements may include company documents, product information, manufacturing details, GMP documents, stability data, certificates, labelling information, and authorisation documents.
The timeline depends on the licence type, product category, documentation, regulatory queries, inspections, and other factors. There is no single guaranteed timeline for all CDSCO applications.
For applicable imported drugs, CDSCO issues a Registration Certificate for eligible foreign manufacturers and products. Form 41 is identified by CDSCO for the Registration Certificate under the applicable Drugs Rules framework.
No. CDSCO and State Licensing Authorities have different regulatory responsibilities. Certain domestic manufacturing, sale, and distribution activities are regulated through State authorities, while CDSCO handles specified central regulatory functions.
Applicable applications submitted through SUGAM can generally be tracked through the applicant's online account and application dashboard.
Yes. Foreign manufacturers can follow the applicable Indian regulatory pathway for importing drugs into India. Depending on the product and activity, registration and import requirements may apply, including the appointment of an authorised Indian representative/agent where required.
Yes. PSR Compliance can assist businesses with CDSCO licence selection, documentation, application preparation, SUGAM submission, regulatory coordination, query responses, and compliance support.
Book your free consultation with our specialists today.
PSR Assistant